Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Whomps Novo Nordisk
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters.
2d
Zepbound users discuss weight loss after preliminary research touts effectiveness
A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...
Axios on MSN
3d
Eli Lilly's GLP-1 outdoes Novo Nordisk's in trial
Adults taking Eli Lilly's
Zepbound
lost 47% more weight on average than those on
Novo
Nordisk
's Wegovy, Lilly reported ...
2d
Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
STAT
4d
Pharmalittle: We’re reading about a Zepbound-Wegovy faceoff, compounders slamming Novo, and more
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback